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Abstract: High doses of delta-9-tetrahydrocannabinol (THC), the main psychoactive component of
cannabis, have been shown to have anxiogenic effects. Additionally, THC effects have been shown to
be modulated by genotype, including the single nucleotide polymorphism (SNP) rs1130233 at the
protein kinase AKT1 gene, a key component of the dopamine signalling cascade. As such, it is likely
that epigenetic methylation around this SNP may affect AKT gene expression, which may in turn
impact on the acute effects of THC on brain function. We investigated the genetic (AKT1 rs1130233)
and epigenetic modulation of brain function during fear processing in a 2-session, double-blind, cross-
over, randomized placebo-controlled THC administration, in 36 healthy males. Fear processing was
assessed using an emotion (fear processing) paradigm, under functional magnetic resonance imaging
(fMRI). Complete genetic and fMRI data were available for 34 participants. THC caused an increase in
anxiety and transient psychotomimetic symptoms and para-hippocampal gyrus/amygdala activation.
Number of A alleles at the AKT1 rs1130233 SNP, and percentage methylation at the CpG11–12 site,
were independently associated with a greater effect of THC on activation in a network of brain regions
including left and right parahippocampal gyri, respectively. AKT1 rs1130233 moderation of the THC
effect on left parahippocampal activation persisted after covarying for methylation percentage, and
was partially mediated in sections of the left parahippocampal gyrus/hippocampus by methylation
percentage. These results may offer an example of how genetic and epigenetic variations influence
the psychotomimetic and neurofunctional effects of THC.
Keywords: THC; cannabis; Marijuana; AKT1; Epigenetics; fMRI
1. Introduction
Worldwide, cannabis is the most popular recreational drug [1]. Commonly smoked,
but also ingested, there are over 140 different cannabinoids in cannabis [2–4], with delta-9-
tetrahydrocannabinol (THC) being the primary psychoactive cannabinoid [4] responsible
for its acute ‘high’ effects. Considerable variability in terms of sensitivity to the acute
effects of cannabis has been found, with cannabis users reporting a wide range of subjective
acute effects that are both positive, such as relaxation, happiness and laughter, as well as
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negative such as anxiety, panic attacks, and, less commonly, paranoia and psychosis-like
symptoms [5].
Consistent with preclinical evidence [6] human experimental evidence suggests that
such variability may be related to the specific dose of THC, with lower doses having
anxiolytic [7] and higher doses having anxiogenic effects [8–11]. Further, the anxiogenic
effects of THC seem to be attenuated when using cannabis strains containing also high-
dose cannabidiol (CBD; [12], the other main cannabinoid in cannabis. In line with this
finding, under experimental conditions, CBD is known to have anxiolytic effects on its
own [13,14], opposite neurophysiological and behavioral effects to those of THC when
separately administered to the same individuals [13,15,16], and counteracting effects when
co-administered along with THC [9,17]. Furthermore, we and others have provided
evidence that sensitivity to the acute effects of THC on symptoms [15], cognition [18] and
their neurophysiological underpinnings [15] as well as to the short-term psychotomimetic
effects of cannabis [19], are moderated by a variation in the AKT1 gene (rs1130233). This
gene codes for the protein kinase AKT, and its rs1130233 single nucleotide polymorphism
(SNP) is a synonymous coding variation that has been linked to differential expression of
the AKT protein, whereby the presence of an A allele is robustly associated with decreased
expression of AKT [20–23].
The protein kinase AKT is a key component of the dopamine signaling cascade [24,25]
and altered AKT activity has been suggested to be relevant for the manifestation of psychi-
atric symptoms, including anxiety-like behaviors [26,27]. Regular cannabis use and acute
THC administration have been shown to alter dopamine signaling in both human [28,29]
and animal [30] studies; and THC has been shown to modulate the phosphorylation of
AKT1 [31,32]. Altered expression of the AKT1 gene may therefore influence sensitivity to
the effects of THC on brain functioning and related behavior, especially anxiety-related
manifestations.
Methylation of DNA, i.e., addition of a methyl group to the cytosine pyrimidine ring
of CpG dinucleotide, is one of several mechanisms of epigenetic control of gene expression,
by reducing it [33]. As such, methylation of the AKT1 gene is likely to reduce its gene
expression and thereby indirectly reduce sensitivity to the acute effects of THC. Although
we have previously demonstrated moderation of the acute effects of THC on functional
brain activation by the AKT1 rs1130233 polymorphism [18,34], whether epigenetic inter-
action around this SNP also influences sensitivity to the acute effects of THC is yet to
be investigated. Therefore, in the present study, we aimed to investigate the effect of an
interaction between AKT1 rs1130233 polymorphism and methylation of CpG sites around
this locus on the acute effect of THC administration on brain activation, during the pro-
cessing of fear, as indexed using functional MRI. We focused on the effects of THC on
fear processing-related brain activation in-light-of previous evidence that a single dose
of THC modulates normal functioning of limbic regions involved in the processing of
fear, in particular the amygdala, which correlated directly with the severity of anxiety
induced by THC acutely [9,13]. We hypothesized that the effect of a single dose of THC on
fear-related activation of limbic regions would be modulated by both the AKT1 rs1130233
polymorphism and the methylation of CpG sites around this locus.
2. Methods
2.1. Participants
Thirty-six right-handed healthy males, mean age 25.97 ± 5.8 years and IQ of 97.7 ± 6
took part in the study. None had a personal or family (first-degree relative) history of
psychiatric illness. The Addiction Severity index was used to asses alcohol, cannabis and
other illicit drug use [35] (Table 1). All had used cannabis at least once but no more than
25 times in their lifetime. None of them consumed illicit drugs regularly or over 21 units
of alcohol per week. They were advised to not use illicit drugs, including cannabis for
30 days prior to the study or between the testing sessions. They were advised to have at
least 8 h sleep the night prior to each study day, and to abstain from consuming caffeine
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for 12 h, tobacco for 4 h, and alcohol for 24 h prior to each study day. All subjects provided
urine samples for drugs testing by immunometric assay kits. Of the subjects, 33 were white
Europeans, two Sri-Lankan and one Chinese.
As genotyping at the AKT1 rs1130233 locus was unsuccessful in 1 participant, asso-
ciation between AKT1 rs1130233 SNP and methylation at CpG sites was investigated in
35 participants. Additionally, as another participant was unable to complete the fMRI
scan under the THC condition, the effect of THC on activation compared to placebo and
its correlation with percentage CpG methylation at site 11–12 were investigated in the
35 subjects. Thus, correlational analyses between genotype and THC effect on brain activa-
tion maps both with and without covarying for CpG methylation was performed in the
34 participants with completed neuroimaging and genotyping data.
Table 1. Previous use of psychoactive substances by participants (amended from our previous
publication [8]).
Lifetime Psychoactive Substance Use
Caffeine 33 subjects; Mean number of cups of coffee, tea or caffeinateddrinks/day-2.42 (SD–1.86) (range 0–11)
Nicotine
9 subjects;
Mean number of cigarettes smoked/day-1.19 (SD–3.18) (range 0–15/day);
2 subjects smoked >10 cigarettes/day lifetime; only 1 subject smoked at
that level at the time of the study.
Cannabis <5 times used = 12 subjects;5–25 times used = 24 subjects
Cocaine A few times of reported use = 3 subjects
Amphetamines A few times of reported use = 5 subjectsUsed small quantities from time to time = 1 subject
LSD/Psilocybin A few times of reported use = 10 subjects
Opiates A few times of reported use = 2 subjects
MDMA A few times of reported use = 11 subjects
2.2. Experimental Design
As previously reported [18,34], each participant was tested on two separate occasions
at least one month apart employing a double-blind, within-subject, crossover design. At
each of the two sessions, they were given either 10 mg of THC (approximately 99.6% pure,
THC-pharm, Frankfurt, Germany) or a placebo (a matched gelatine capsule). To ensure
that a roughly equal number of participants received THC or the placebo at each session,
the order of drug administration was pseudo-randomised.
On the morning of each session, all participants passed a urine drug screening for opi-
ates, cocaine, amphetamines, benzodiazepines and THC, using immunometric assay kits.
Venous blood samples and psychopathological ratings were taken at baseline, and one, two
and three hours post drug administration. A blood sample for genotyping and methylation
analysis was obtained at baseline. Psychotomimetic effects were assessed by a clinician
using the positive negative symptom scale (PANSS) [36]. Spielberger state-trait anxiety
inventory- state subscale (STAI-state) was used to measure self-rated anxiety [37]. The
analogue intoxication scale (AIS) was used to measure self-rated intoxication sedation [38],
and the visual analogue mood scale was used to measure self-reported sedation (VAMS; the
mental sedation subscale) [39]. Subjects were scanned one hour after administration of THC
or placebo. Pilot studies showed that the concentration of THC in blood samples plateaued
and remained stable at approximately 1 to 2 h after ingestion of the drug. We therefor
performed MRI scans from 1 h after administration of the drug and the scans lasted for no
more than 1 h. During this scan participants completed the emotional processing task.
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2.3. Image Acquisition
Images were acquired on a 1.5 Tesla Signa System (GE) at the Institute of Psychiatry,
Psychology & Neuroscience, London. T2*—weighted images were taken using TR of
2000 ms; with 40 ms echo time; a flip angle of 90◦ in 16 axial planes 7 mm thick, parallel
to anterior commissure posterior commissure line. To facilitate anatomical localisation
of activation and high-resolution inversion recovery image dataset was acquired using
a 3 mm contiguous slices and an in-plane resolution of 3 mm (TR 16,000 ms, Ti 180 ms,
TE ms).
2.4. fMRI Task
Inside the scanner, participants performed the emotional (fear) processing task, which
has been described in detail elsewhere [10,40]. The blood oxygen level-dependant (BOLD)
haemodynamic response was measured in subjects while they viewed faces that are neutral,
mild or intensively fearful, or a crosshair. The subjects were asked to indicate the gender
of the faces shown on the screen using a button-box. The faces were pseudo-randomised,
each face was viewed for two seconds while the subjects were asked to press one of two
buttons to determine the sex of the face. During the inter-stimulus interval, subjects were
shown a fixation cross for 3–8 s according to a Poisson distribution. Performance data
were collected in the form of reaction time and accuracy while indicating the gender of the
facial stimuli.
2.5. Genotyping and Methylation Assay
DNA was extracted using standard methods by researchers at the Institute of Psychi-
atry [41] and Genotyped for the AKT1 G>A rs1130233 SNP by KBioscience (Herts, UK;
http://www.kbioscience.co.uk/, accessed on 28 July 2021) successfully for 35 out of the 36
subjects (corresponding to a call rate of 97%). Genotype frequencies and socio-demographic
details of the 35 subjects are shown in Table 2. Genotype groups did not differ statistically
significantly (p < 0.05) with regard to age, NART IQ or the number of years of education.
Genotype frequencies for AKT1 at rs1130233 were in Hardy-Weinberg equilibrium (HWE;
χ2 = 2.14, p > 0.05) in the ethnically stratified sample.
Table 2. Participants by genotype, average age, NART IQ and education.
Genotype Age (Mean ± SD) p NART IQ(Mean ± SD) p
Number of Years of
Education (Mean ± SD) p
AKT1(G/G) (n = 19) 26.5 ± 5.8 NS 98.8 ± 6.9 NS 17.5 ± 3.2 NS
AKT1(G/A) (n = 9) 26.3 ± 4.7 97.9 ± 5.3 16.6 ± 3.3
AKT1(A/A) (n = 7) 23.8 ± 6.6 95.5 ± 8.0 17.0 ± 7.4
The DNA methylation assay was carried out using previously described methods [42].
Briefly, DNA samples were treated with sodium bisulfite using the EZ-96 DNA Methylation
Kit (Zymo Research Corporation, Irvine, CA, USA) following the manufacturer’s protocol.
Bisulfite–PCR amplification was conducted using Hot Star Taq DNA polymerase (Qiagen,
UK). The primers used were GTTTTTGTTGAGTTAGGGTTTTTGA for the forward strand
and TCCTTATCCAACATAAAATTCTCCA for the reverse strand, designed using the
Sequenom EpiDesigner software (http://www.epidesigner.com, accessed on 28 July 2021).
A total of 19 CpG sites were analysed in 14 CpG island blocks. This was such that CpG
sites 6 and 7, 9 and 10, 11 and 12, 17 and 18, were analysed as a single site, due to their
close proximity and high numbers of C and G nucleotides in between them, making
them difficult to distinguish individually. Reactions were performed in duplicate and
methylation analysis was carried out following established [43] using the Sequenom
EpiTYPER platform (Sequenom Inc., San Diego, CA, USA), a reliable way of finding
the density of methylated cytosines at specific genomic loci. Base-specific cleavage is
followed by matrix-assisted laser desorption/inonization-time of flight (MALDI-TOF)
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mass spectrometry. The size ratio of the cleaved products then provide methylation
estimates for each cytosine-phosphate-guanine (CpG) unit, containing either one or an
aggregate of neighbouring CpG sites. EpiTYPER software generated data that underwent
stringent quality-control analysis where only CpG units with high calling rates (>80%)
survived for statistical analyses.
Genotyping and methylation assays were carried out blind to THC response results.
As a number of CpG sites are present around the rs1130233 locus, association between
genotype and methylation status at each of these sites was examined first in order to
identify the specific CpG sites to be further investigated in the present study. As there was
a significant association between AKT1 rs1130233 genotype and methylation percentage at
CpG sites 11–12 (CpG11–12, Chr14: 104,773,527–104,773,522) around this locus (tested using
a t-test), which survived correction for multiple testing (uncorrected p < 0.001; corrected
threshold p = 0.0027), we focused on methylation at these sites for subsequent analyses.
2.6. Image Analysis
The images were analysed using a non-parametric software package, XBAM_v4.1,
that was developed at the Institute of Psychiatry, Psychology & Neuroscience (King’s
College London). It is important to use non-parametric measures when analysing fMRI
data as it may not follow a normal Gaussian distribution [44,45]. Also, XBAM is less
likely to misrepresent data distributions from outlier values as it uses medians rather than
averages [46]. The test statistic is calculated by standardizing for individual differences
in residual noise before beginning second-level, multi-subject testing, that uses a mixed
effect-approach and robust permutation-based method.
Firstly, correction for head motion was completed by realigning the images, to a
template created by computing a 3D volume from the average intensity at each voxel
throughout the whole period scanning [47]. Realignment of the 3D image volume at each
time-point to the template was computing using a combination of rotations (around the
x, y and z axes) and translations (in x, y and z) that maximised the correlation between
the template 3D volume and the image intensities of the volume in question. In order
to smooth the data a 7.2 mm full-width-at-half-maximum Gaussian filter was applied
to average the relative intensities of neighbouring voxels. Individual activation maps
were created by modelling the BOLD signal using 2 gamma-variate functions for each
experimental condition, peaking at 4 and 8 s to allow for variability in haemodynamic
delay. A best fit between the weighted sum of these convolutions and the change over time
was computed at each voxel using the constrained BOLD effects model [48]. This method
increases the robustness of the model fitting procedure to not give mathematically plausible,
but physiologically implausible results. The sum of squares (SSQ) ratio (calculated as the
ratio of the SSQ of deviations from the mean image intensity due to the model component
over the whole time series to the SSQ of deviations due to the residuals) was estimated for
each voxel, followed by permutation testing, determining which voxels were significantly
activated [49]. This avoids F statistic associated problems, where in fMRI time series the use
of the residual degrees of freedom are often unknown due to coloured noise in the signal.
Data was then permuted by the wavelet-based method; both described and characterized
previously [49], this permits a data driven calculation of the null distribution of SSQ, by
assuming no experimentally-determined response. This distribution was then used to
threshold the activation maps at the desired Type 1 error rate of less than one false positive.
Indervidual SSQ ratio maps were transformed into standard stereotactic space [50] using
a two-stage warping procedure [44] allowing for localization of activations. Initially an
individual average image intensity map over the course of the experiment was computed,
followed by computation of the affine transformations required to map this image to first
their structural scan and then to the Talairach template, by maximizing between image
correlations at each stage. The BOLD effect size and SSQ ratio maps were transformed into
Talairach space using these transformation methods.
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Group activation maps were created for each task condition (‘intensely fearful faces’,
‘mildly fearful faces’, ‘neutral faces’), and for each drug condition (THC, placebo). Median
SSQ ratios at each voxel across all individuals were determined in the observed and
permutated data maps, using medians to minimize outlier effects. A null distribution of
SSQ ratios was driven from the distribution of median SSQ ratios over all intracerebral
voxels from the permuted data, giving group activation maps for each condition. We
could then directly compare group activation at each condition using non-parametric
repeated-measure analysis of variance (ANOVA) [44].
Activated voxels were grouped into clusters of activation using a method previously
described [51] and shown to give excellent cluster-wise Type 1 error control. A voxel-wise
statistical threshold of p = 0.05 was used and the cluster-wise thresholds were chosen such
that the number of false positive clusters would be <1 per brain (therefor we have only
reported regions that survive both the critical statistical threshold and the corresponding
p values from cluster-level analysis). The data from more than one voxel is integrated
into the test statistic giving greater sensitivity and allows for a reduction in the search
volume or overall number of required tests for whole brain analysis, thereby helping to
mitigate the problem multiple comparisons. For each drug condition, we therefore had a
separate standard-space map for each of the experimental conditions (‘intensely fearful
faces’, ‘mildly fearful faces’ or ‘neutral faces’) for each participant. We then employed a
non-parametric repeated measures analysis of variance (ANOVA) whole-brain analysis
approach to identify brain regions that were activated by THC relative to the placebo
condition. We contrasting the individual brain activation maps for intense and mildly
fearful faces combined (as the fear condition) with those of the neutral faces.
As we were interested in investigating the relationship of AKT1 rs130233 genotype
and methylation (at CpG site 11–12 around that locus) with the cerebral activation response
to THC during fear processing, we followed the Baron and Kenney [52]. mediation analysis
approach to examine whether methylation at CpG site 11–12 (moderator variable) mediated
the relationship between brain activation during fear processing (dependent variable) and
AKT1 SNP rs1130233 (independent variable). Therefore we investigated the association
between independent variable (genotype) and dependent variable (brain activation), then
between moderator variable (methylation) and dependent variable and between moderator
variable and independent variable by carrying out separate correlational analyses. Finally,
to investigate the extent to which the association between genotype and THC effect on
fear-related brain activation was mediated by methylation at the CpG 11–12 site, we carried
out a final correlational analysis between genotype (AKT1 rs130233) and the effect of THC
on brain activation during fear processing, while covarying for methylation percentage at
the CpG site 11–12.
These analysis examined the association between the median SSQ ratio under each
drug condition (THC and placebo) while processing fear with: (1) genotype (“number
of A alleles +1”, at the AKT1 rs1130233 locus, coded as G/G = 1 G/A = 2 and A/A = 3);
and (2) DNA methylation (methylation percentage at CpG site 11–12). We contrasted
each of the active (‘intensely fearful faces’ and ‘mildly fearful faces’) conditions of the
fear processing task with the baseline condition (‘neutral faces’) to generate contrast
of interest maps (‘intense fear’ map: ‘intensely fearful minus neutral face’; ‘mild fear’
map: ‘mildly fearful minus neutral face’) for each individual participant under each
drug condition. We estimated the Pearson’s product moment correlation coefficient at
each voxel, in each subject’s standard space, yielding one correlation coefficient (r) per
intracerebral voxel. Correlation differences between groups were estimated at each voxel
by computing for each group, the r value for each subject followed by subtracting the
resulting two values. A null distribution was then appropriately generated by randomly
permuting subjects and their associated genotype or methylation levels between the groups
(without replacement), therefore scrambling any group differences. For each permutation,
the difference in correlation between the scrambled groups was calculated and then the
resulting values combined for all voxels to produce a whole-brain null distribution of
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differences in correlation. The critical value for significance at any desired Type 1 error
level in the original (non-permuted) data were then obtained from this distribution after
sorting it and selecting the appropriate point from the sorted distribution. This means that
the critical value for a one-tailed test thresholded at p = 0.05 would be the value of the
difference in correlation in the null distribution where 95% of all the null values lay below
that point. The statistical analysis was then extended to the 3D cluster level, previously
described [51]. The probability for each cluster was chosen to set the level of expected Type
I error clusters to less than 1 error cluster per whole brain under the null hypothesis.
3. Results
3.1. Participants
All subjects had used cannabis at least once, but no more than 25 times in there lifetime.
No participant consumed more than 21 units of alcohol per week, and all had low levels of
illicit drug use. None of the participants had used cannabis or other illicit drugs for at least
one month prior to their first visit, and they were asked to abstain from use between visits.
Substances use information in this cohort of participants has been reported previously [8].
It has been presented again in this manuscript in the form of an amended table (Table 1)
for the sake of completeness.
Genotype frequencies of participants showed no difference between groups with
regard to age, NART IQ and number of years of education, shown in Table 2 for all
35 participants successfully genotyped. Genotype data for both genetic variants were tested
for deviation from Hardy-Weinberg equilibrium (HWE). Frequencies for AKT1 rs1130233
showed a deviation from the HWE (χ2 = 6.0, p < 0.05). However, the AKT1 rs1130233
polymorphism was retained consistent with current practice, as there was no evidence
of a quality control issue and also as recent evidence suggests that while polymorphisms
that are not in HWE may be less powerful, they do not tend to increase false positive
results [53].
3.2. Symptomatic and Behavioural Response to THC
These results have been previously reported in detail by [8], however, we are sum-
marising them here again for completeness. As we have previously reported [8] administra-
tion of THC was associated with change in psychopathological ratings over time (estimated
as the area under the curve; AUC). In particular, THC administration was associated with
the induction of transient positive psychotic symptoms (as indexed using the PANSS posi-
tive symptoms subscale; THC (AUC) = 25.83 ± 6.0, Placebo (AUC) = 21.96 ± 1.8, p < 0.001)
and anxiety symptoms (as indexed using the STAI-state, THC (AUC) = 49.36 ± 27.6, PLB
(AUC) = 37.12± 22.3, p < 0.001). Additionally, a THC-induced change in total PANSS scores
(THC (AUC) = 108.61 ± 16.6, PLB (AUC) = 94.49 ± 6.4, p < 0.001) and levels of sedation (as
indexed using the VAMS, THC (AUC) = 54.98 ± 14.8, PLB (AUC) = 48.65 ± 16.2, p = 0.02;
shown in our previous publication [8]) and intoxication (as indexed using the AIS, THC
(AUC) = 9.99 ± 5.5, PLB (AUC) = 3.64 ± 4.4, p < 0.001) were observed.
There was no significant effect of drug condition on reaction time during the emotional
(fear) processing task (p = 0.597) or performance accuracy across all emotional conditions
(p = 0.933) as well as for fear (p = 0.976). There was no statistically significant effect of
drug condition on reaction time during the emotional (fear) processing task (p = 0.597) or
performance accuracy across all emotion conditions (p = 0.933) as well as for fear (p = 0.976).
3.3. Regional Brain Response to THC during Fear Processing
There was a statistically significant effect of THC administration on the normal pattern
of regional brain activation associated with fear in a distributed network of regions includ-
ing the left parahippocampal gyrus and amydgala. THC enhanced left parahippocampal
gyrus/amydgala engagement while viewing fearful faces compared to neutral faces, while
there was an attenuation of engagement in these regions under placebo while viewing
fearful faces relative to neutral faces (Figure 1).
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3.4. Relationship between AKT1 Genotype (rs1130233) and the Effect of THC on Regional Brain
Activation during Fear Processing
There was a statistically signific t association between the effect of THC on regional
brain activation while processing fear and AKT1 genotype (rs1130233), such that the
higher the number of risk alleles (A) the greater was the effect of THC on fear-related
brain activation across a network of brain regions (Figure 2A and Table 3) that included
parahippocampal, fusiform and cingulate gyri. Additionally, a cluster in the left anterior
cingulate gyrus/medial prefrontal cortex (x = −11, y = 26, z = 26; rho = 0.395, p = 0.021)
correlated positively with change in STAI scores.
Table 3. Regions of brain activation (Talairach coordinates) showing significantly greater correlation
with the number of A alleles of the AKT1 rs1130233 polymorphism under THC condition than under
placebo condition while viewing fearful faces. L and R indicate the left and right hemisphere.
Cerebral Region x y z Size (No. of Voxels) Side p-Value
Inferior Frontal Gyrus
−43 26 4 14 L
0.006583
−40 26 −2 22 L
−32 22 −13 15 L
−36 19 −7 17 L
Anterior Cingulate Gyrus
−4 22 37 10 L
0.002992
−11 30 20 15 L
Fusiform Gyrus −22 −67 −7 8 L 0.002992
Cuneus −11 −74 15 10 L 0.002992
Middle Occipital Gyrus
−29 −63 4 5 L
0.002992−25 −81 9 25 L
−18 −85 15 8 L
Culmen
−18 −44 −7 5 L 0.001496
−22 −44 −18 7 L 0.008378
Middle Temporal Gyrus
−51 −33 −13 63 L
0.001496
−51 −11 −13 7 L
Brainstem, Midbrain 0 −15 −18 5 R 0.001496
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Table 3. Cont.
Cerebral Region x y z Size (No. of Voxels) Side p-Value
Parahippocampal gyrus
−40 −30 −7 30 L
0.001496
−25 −26 −18 12 L
Cingulate Gyrus
−7 19 42 5 L
0.002992−11 26 26 14 L
−11 26 31 10 L
Anterior Cingulate
0 30 15 20 R
0.002992−7 33 9 13 L
0 37 4 7 R
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3.5. Relationship between Methylation at CpG11–12 Site around AKT1 SNP (rs1130233) and the
Effect of THC on Regional Brain Activation during Fear Processing
There was a significant association between the effect of THC on regional brain
activation while processing fear, and methylation at CpG11–12 site, such that the higher
the percentage of methylation at this site, the greater was the effect of THC on fear-related
brain activation across a network of brain regions (Figure 2B and Table 4) that included
parahippocampal and cingulate gyri. Anxiety induced under the influence of THC (indexed
using STAI) correlated positively with its effect on parahippocampal activation (x = 29,
y = −22, z = −13; rho= 0.401, p = 0.017).
Table 4. Regions of brain activation (Talairach coordinates) showing significantly greater correlation
with methylation percentage at CpG island 11–12 around rs1130233 polymorphism in the AKT1 gene
under THC condition than under placebo condition while viewing fearful faces. L and R indicate the
left and right hemisphere.
Cerebral Region x y z Size (No. of Voxels) Side p-Value
Superior Frontal Gyrus 36 52 15 27 R 0.003249
Medial Frontal Gyrus
40 48 9 11 R
0.003249
43 37 20 9 R
43 7 42 20 R
0.00206740 11 37 26 R
40 7 48 15 R
0 −4 53 9 R 0.005907
Inferior Frontal Gyrus
51 26 20 12 R 0.003249
43 4 31 17 R 0.002067
Sub-Gyral
40 15 15 12 R 0.003249
11 30 −2 8 R
0.002658−43 −33 −7 18 L
−47 −15 −13 5 L
−25 7 42 26 L
0.005907−29 7 37 10 L
−32 −4 37 6 L
25 −4 53 23 R 0.007383
−29 −70 26 5 L 0.009155
Middle Occipital Gyrus
−25 −78 15 9 L
0.009155
−25 −74 9 8 L
Middle Temporal Gyrus −29 −70 20 11 L 0.009155
Precentral Gyrus 29 −15 48 21 R 0.007383
Precuneus. −36 −70 37 5 L 0.009155
Angular Gyrus −36 −74 31 6 L 0.009155
Fusiform Gyrus. −32 −37 −18 18 L 0.002658
Midbrain −4 −26 −13 47 L 0.002658
Left Brainstem, Midbrain −4 −22 −18 6 L 0.002658
Insula 40 15 9 13 R 0.003249
Extra-Nuclear Corpus Callosum
4 15 20 12 R
0.002658
−4 26 −2 8 L
Amygdala/Parahippocampal gyrus 22 −7 −18 36 R 0.003249
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Table 4. Cont.
Cerebral Region x y z Size (No. of Voxels) Side p-Value
Parahippocampal Gyrus 29 −22 −13 23 R 0.003249
Anterior Cingulate
0 37 4 9 R
0.0026584 33 9 6 R
0 30 15 19 R
3.6. Relationship between Methylation at CpG11–12 Site around AKT1 SNP (rs1130233) and the
Number of A Alleles at AKT1 SNP (rs1130233)
As expected, there was a linear relationship (r = 0.869, p ≤ 0.001) between the number
of A alleles at AKT1 rs1130233 and methylation percentage at CpG sites 11–12, (therefore
the higher the number of A alleles the higher the methylation percentage).
3.7. Relationship between AKT1 Genotype (rs1130233) and the Effect of THC on Regional Brain
Activation during Fear Processing after Covarying for Methylation at CpG11–12 Site
On investigating whether the association between AKT1 rs1130233 genotype and
THC-induced change in brain activation while processing fear was mediated by degree
of methylation at the CpG11–12 site, we found that some of the association between AKT1
rs1130233 polymorphism and effect of THC on fear-related brain activation (as depicted in
Figure 2A and Table 1) was no longer present (as depicted in Figure 2C and Table 5) after
covarying for percentage methylation at the CpG11–12 site. This suggested that methylation
percentage at the CpG11–12 site partly mediated some of the association between AKT1
rs1130233 polymorphism and the effect of THC on fear-related brain activation. Brain
regions where the association between AKT1 rs1130233 genotype and THC’s effect on fear-
related activation were mediated by percentage methylation at the CpG11–12 site around
AKT1 rs1130233 localize to the left parahippocampal gyrus extending toward the lingual
gyrus, left fusiform gyrus, midbrain extending to the left parahippocampal gyrus, left
hippocampus extending towards the insula and the left superior temporal gyrus (Figure 2D
and Table 6).
Table 5. Regions of brain activation (Talairach coordinates) showing significantly greater correlation
with the number of A alleles of the AKT1 rs1130233 polymorphism under THC condition than under
placebo condition while viewing fearful faces after controlling for percentage methylation at CpG
island 11–12 around rs1130233 polymorphism in the AKT1 gene. L and R indicate the left and
right hemisphere.
Cerebral Region x y z Size (No. of Voxels) Side p-Value
Middle Frontal Gyrus
40 52 4 3 R
0.005075
36 48 9 7 R
36 48 15 21 R
−36 44 9 17 L
−40 41 15 13 L
40 37 20 8 R
Medial Frontal Gyrus
0 33 42 9 R
0.005075
0 30 37 15 R
Inferior Frontal Gyrus
40 26 4 7 R
0.00507540 26 −7 5 R
−47 19 4 13 L
Middle Temporal Gyrus
−51 −11 −13 7 L
0.007761
−51 −33 −13 63 L
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Table 5. Cont.
Cerebral Region x y z Size (No. of Voxels) Side p-Value
Sub-Gyral
−32 44 4 12 L 0.005075
−40 −30 −7 28 L
0.007761
−36 −37 −2 4 L
Middle Occipital Gyrus
−22 −85 15 9 L
0.007761
−29 −63 4 5 L
Culmen. −18 −44 −7 4 L 0.007761
Cuneus
−11 −74 15 10 L
0.007761
−18 −85 20 3 L
Extra-Nuclear
−32 22 −2 25 L
0.00507532 22 −2 7 R
−32 15 −7 25 L
Left Brainstem, Midbrain 0 −15 −18 4 R 0.007761
Parahippocampal Gyrus −25 −26 −18 18 L 0.007761
Posterior Cingulate −22 −67 9 27 L 0.007761
Cingulate Gyrus
−7 19 42 7 L
0.005075−11 26 26 15 L
−11 26 31 14 L
Anterior Cingulate
−11 26 20 17 L
0.005075
0 30 15 22 R
−4 33 9 12 L
0 37 4 7 R
Table 6. Clusters of brain activation where the significantly greater correlation between the number
of A alleles of the AKT1 rs1130233 polymorphism under THC condition than under placebo condition
while viewing fearful faces may be mediated by correlation with methylation percentage at CpG
island 11–12 around rs1130233 polymorphism in the AKT1 gene. L and R indicate the left and
right hemisphere.
Tal(x) Tal(y) Tal(z) Cerebral Region
−22 −50 0 Parahippocampal Gyrus/Lingual Gyrus
−33 −45 −10 Fusiform
−11 −27 −10 Midbrain −> parahippocampal gyrus
−34 −26 −7 Hippocampus −> Insula
−48 −1 −7 Superior Temporal gyrus
4. Discussion
Here we investigate the independent effects of AKT1 SNP rs1130233 genotype and
methylation levels at its surrounding CpG sites as well as their relationship with fear-related
brain activity and associated anxiety-like behaviour in healthy individuals while they were
under the acute influence of experimentally administered THC. We found an association
between genotype alone and THC effect on brain activation, such that, following acute
THC exposure allele A (previously shown to moderate sensitivity to the acute psychoactive
effects of THC [18,34] was associated with greater activation in the parahipocampal and
cingulate gyri during fear processing. Similarly, we found that, following acute THC
exposure, increased methylation percentage around the SNP locus was associated with
greater activation in the same brain regions whilst fear processing. Additionally, the greater
the activation of such brain regions, the more severe were the anxiety symptoms following
acute THC administration. Finally, the most novel finding from this study is that, following
acute THC exposure, methylation around the rs1130233 SNP partially mediated the effect
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of AKT1 genotype on fear processing in the parahippocampal gyrus and hippocampus,
extending to the STG and insula.
Convergent evidence from both animal [54] and human [23] studies implicates AKT1
in modulating prefrontal-striatal structure and function and suggests that its deficiency
creates a context permissive for gene-gene and gene-environment interactions that con-
tribute to altered dopaminergic transmission, increasing the risk of dopamine-associated
disorders and behaviours. Consistent with this, several previous studies have indicated
that genetic variations in the AKT1 gene may moderate the acute psychotogenic effects of
cannabis [18,23,34,54,55], although this has not been confirmed by one recent study [56],
possibly due to differences in study design. The present study extends such findings
indicating that the rs1130233 polymorphism of the AKT1 gene also moderates the acute
effects of THC on the neurophysiological underpinnings of fear processing and associated
anxiety-like behaviour.
Previous work has explored how continued exposure to cannabis and its main psy-
choactive compound THC may result in aberrant epigenetic modifications, including
altered methylation [57] However, limited investigation has been carried out so far on
how epigenetic mechanisms may modulate behavioural responses to cannabis, including
psychotomimetic symptoms. While increased methylation from another dopamine-related
gene, catechol-O-Methyltransferase (COMT), has been associated with lower cannabis use
frequency during adolescence [58] the present study is the first to investigate the effects
of methylation in the AKT1 gene on brain functioning and related behaviour following
acute THC exposure. Specifically, under the effects of THC, we found greater functional
activation in fear processing-related brain regions and more severe associated anxiety, as a
function of increasing AKT1 methylation. Methylation levels also partially mediated the
modulatory effect of genetic variation in the AKT1 gene on acute THC-induced activation
of brain regions involved in fear processing.
While viewing neutral faces, acute THC exposure decreased brain activation consistent
with the known effects of cannabis [59] on brain activation [60,61]. Instead, acute THC
administration increased activation when viewing fearful faces in limbic regions such as
the parahippocampal gyrus and amygdala. As such increase in fear processing-related
brain activation was associated with both the load of AKT1 rs1130233 allele A and related
methylation (and thus lower gene expression), then altered AKT1 activity may therefore
represent a marker for differing responses to fear processing under the acute effects of
cannabis. More specifically, the THC-induced increase in brain activation in several brain
regions involved in emotional processing as a function of both these genetic factors may
possibly represent a genetically mediated lack of efficiency in processing emotion, similar
to that found by previous studies [45,54]. Such explanation would be corroborated by the
evidence that two clusters in the cingulate gyrus and inferior frontal gyrus also positively
correlated with the STAI score, an indication that increased activation in these brain regions
may reflect higher levels of anxiety.
Presence of the A allele at this SNP has been associated with lower AKT1 expression [20–23]
and increased methylation levels usually do also often have the effect of decreasing gene
expression [33]. As both the rs1130233 A allele and increased methylation around this
locus were associated with THC-induced increased activation in a number of brain regions,
such neurophysiological effects of the drug could be due to the effect of both genotype
and methylation in reducing AKT1 gene expression [62]. Acute THC exposure has been
shown to result in an increase in dopamine release [63] via a CB1 receptor-dependent
modulation of glutamate [64–66] and GABA signalling [67], leading to the manifestation of
psychotomimetic symptoms [66]. Dopamine binding at its receptors has an inhibitory effect
on AKT1 action [68] and THC has also been reported to induce the phosphorylation of
AKT1 [69], reducing AKT action even beyond acute intoxication. THC-induced dopamine
release may therefore be increased in the context of genetically-determined lower AKT1
gene expression, because of reduced feedback regulation in the cascade where the AKT
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protein is present, as well as because of a direct action of THC in reducing the expression
of the AKT protein [31].
Differing neurophysiological and behavioural effects of acute THC exposure, depen-
dent on AKT1 genetic variation, with mediation via methylation levels, may begin to offer
examples for specific genetic markers that are associated with an increased risk for neu-
ropsychiatric disorders following cannabis use. AKT1 signalling cascade affects dopamine
2 (D2) receptors, encoded by the DRD2 gene, known to play a key role in psychosis [70]
and decreased AKT1 expression could result in an increased level of synaptic activation
through the inhibitory effects from dopamine binding on the enzyme [71]. Consistent with
this, another SNP in the AKT1 gene, rs2494732, which is in high linkage disequilibrium
with rs1130233 (r2 = 0.45, D′ = 0.94), entails a variant—allele A—which has been shown to
increase the risk of developing psychosis among cannabis users [72] and to interact with
genetic variation in the DRD2 gene in further increasing the risk of psychosis possibly
because of genetically-determined higher striatal dopamine levels [73].
By covarying for methylation levels around the genotype locus, the present findings
can only be used to make suggestive comments about the effect of methylation. Therefore,
replication of our results is required to gain stronger evidence into the independent effect
of methylation and to further investigate the specific brain regions potentially involved.
Additionally, the results from this study should only be considered as preliminary due
to the small number of participants. This study also only included male participants
limiting the application of our findings, similar studies should be conducted including
females. This single gender group however, removed the need for examination of a
gender effect on methylation [74] and acute THC response [75] in a small number of
participants, maintaining power in our analysis. Furthermore, the relationship between
peripheral epigenetic markers and brain levels is still uncertain. Future studies should
try to examine methylation as a possible attenuation mechanism for gene expression,
regardless of genotype and alongside genotype, and how it mediates the effects of acute
THC exposure at the molecular level. Other SNPs in the AKT1 gene also warrant further
research to identify their role in gene expression and how they modulate THC response.
This study is further limited using a 1.5 Tesla scanner; as more powerful scanners has now
become more routinely available.
5. Conclusions
In conclusion, this work further adds to existing evidence for a role of the AKT1
SNP rs1130233 in modulating the acute effects of THC during fear processing, with these
being associated with the A allele presence. Additionally, we have provided the first
suggestive evidence that methylation around the SNP, may also independently modulate
such acute response to THC. Finally, methylation levels mediated the effect of the AKT1 SNP
rs1130233 in increasing brain activation following acute THC exposure whilst processing
fear, suggesting a mechanism of further divergence in individuals’ anxiogenic responses
to cannabis.
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